GENinCode (LON:GENI) Stock Price Up 11.8% – Time to Buy?

GENinCode Plc (LON:GENI) shares traded up 11.8% during mid-day trading on Tuesday . The stock traded as high as GBX 1 and last traded at GBX 0.95. Approximately 6,288,954 shares changed hands during mid-day trading, an increase of 14% from the average daily volume of 5,528,808 shares. The stock had previously closed at GBX 0.85.

GENinCode Price Performance

The company has a debt-to-equity ratio of 117.74, a quick ratio of 15.88 and a current ratio of 0.93. The company has a market cap of £7.15 million, a price-to-earnings ratio of -0.46 and a beta of 0.59. The business has a fifty day moving average price of GBX 0.90 and a 200 day moving average price of GBX 1.05.

GENinCode (LON:GENI) last released its quarterly earnings data on Monday, June 8th. The company reported GBX (2.08) earnings per share for the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. The business had revenue of GBX 308 million during the quarter. As a group, research analysts anticipate that GENinCode Plc will post -7.1299999 earnings per share for the current year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.